Stifel analyst Dae Gon Ha upgraded Fulcrum Therapeutics to Buy from Hold with an $11 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics (NASDAQ:FULC) Skyrockets After FDA Lifts Clinical Hold on Sickle Cell Disease Candidate
- FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics names Alan Musso as CFO
- Fulcrum Therapeutics expects cash to fund operations into mid-2025